Last reviewed · How we verify
SDN-037
SDN-037 is a small molecule that targets the SGLT2 receptor.
SDN-037 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SDN-037 |
|---|---|
| Sponsor | Sun Pharma Advanced Research Company Limited |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SDN-037 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SDN-037 CI brief — competitive landscape report
- SDN-037 updates RSS · CI watch RSS
- Sun Pharma Advanced Research Company Limited portfolio CI